The Treatment of Chronic Constipation in Adults a Systematic Review Doi

1. Longstreth, GF, Thompson, WG, Chey, WD, Houghton, LA, Mearin, F, and Spiller, RC (2006). Functional bowel disorders. Gastroenterology. 130, 1480-1491.

   

2. Drossman, DA, and Dumitrascu, DL (2006). Rome 3: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 15, 237-241.

   

3. Sonnenberg, A, and Koch, TR (1989). Epidemiology of constipation in the United States. Dis Colon Rectum. 32, i-eight.

   

4. Locke, GR, Pemberton, JH, and Phillips, SF (2000). AGA technical review on constipation. American Gastroenterological Association. Gastroenterology. 119, 1766-1778.

   

5. M?ller-Lissner, SA (1988). Effect of wheat bran on weight of stool and gastrointestinal transit fourth dimension: a meta analysis. Br Med J (Clin Res Ed). 296, 615-617.

   

6. Petticrew, One thousand, Rodgers, Thousand, and Booth, A (2001). Effectiveness of laxatives in adults. Qual Health Care. 10, 268-273.

   

7. Borum, ML (2001). Constipation: evaluation and management. Prim Care. 28, Array-590.

   

8. Chaussade, S, and Mini?, M (2003). Comparing of efficacy and prophylactic of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther. 17, 165-172.

   

9. Bouhnik, Y, Neut, C, and Raskine, 50 (2004). Prospective, randomized, parallel-grouping trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther. 19, 889-899.

   

10. Attar, A, 50?mann, M, and Ferguson, A (1999). Comparing of a depression dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 44, 226-230.

    

11. Cleveland, MV, Flavin, DP, Ruben, RA, Epstein, RM, and Clark, GE (2001). New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. Southward Med J. 94, 478-481.

    

12. Corazziari, E, Badiali, D, and Bazzocchi, G (2000). Long term efficacy, safe, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte counterbalanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 46, 522-526.

    

14. Ramkumar, D, and Rao, SSC (2005). Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 100, 936-971.

    

15. Muller-Lissner, SA, Kamm, MA, Scarpignato, C, and Wald, A (2005). Myths and misconceptions about chronic constipation. Am J Gastroenterol. 100, 232-242.

    

16. Shafik, A, Shafik, AA, el-Sibai, O, and Ahmed, I (2003). Colonic pacing in patients with constipation due to colonic inertia. Med Sci Monit. ix, CR243-CR248.

17. Kenefick, NJ, Vaizey, CJ, Cohen, CRG, Nicholls, RJ, and Kamm, MA (2002). Double-blind placebo-controlled crossover study of sacral nerve stimulation for idiopathic constipation. Br J Surg. 89, 1570-1571.

    

18. Chang, HS, Myung, SJ, and Yang, SK (2003). Effect of electrical stimulation in constipated patients with impaired rectal sensation. Int J Colorectal Dis. 18, 433-438.

    

19. Drossman, DA, Toner, BB, and Whitehead, We (2003). Cognitive-behavioral therapy versus pedagogy and desipramine versus placebo for moderate to astringent functional bowel disorders. Gastroenterology. 125, 19-31.

    

20. Heymen, S, Wexner, SD, Vickers, D, Nogueras, JJ, Weiss, EG, and Pikarsky, AJ (1999). Prospective, randomized trial comparing four biofeedback techniques for patients with constipation. Dis Colon Rectum. 42, 1388-1393.

    

21. Heymen, Southward, Jones, KR, Scarlett, Y, and Whitehead, Nosotros (2003). Biofeedback treatment of constipation: a critical review. Dis Colon Rectum. 46, 1208-1217.

    

22. Altabas, K, Bili?, A, and Jurci?, D (2003). The efficacy of cisapride vs. placebo and diet in patients with chronic constipation. Coll Antropol. 27, 197-204.

    

23. Johanson, JF, Wald, A, and Tougas, G (2004). Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2, 796-805.

    

24. Johanson, JF (2004). Review article: tegaserod for chronic constipation. Aliment Pharmacol Ther. xx, 20-24.

    

25. Kamm, MA, Grand?ller-Lissner, S, and Talley, NJ (2005). Tegaserod for the treatment of chronic constipation: a randomized, double-bullheaded, placebo-controlled multinational study. Am J Gastroenterol. 100, 362-372.

    

26. Cash, BD, and Lacy, Exist (2006). Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol. ii, 736-749.

27. Orr, KK (2006). Lubiprostone: a novel chloride aqueduct activator for the treatment of constipation. Formulary. 41, 118-120.

28. Winpenney, JP (2005). Lubiprostone. I Drugs. 8, 416-422.

29. Johanson, JF, Gargano, MA, Holland, PC, Patchen, ML, and Ueno, R (2005). Stage Three study of lubiprostone, a chloride channel-2 (CIC-2) activator for the treatment of constipation: safety and primary efficacy. Am J Gastroenterol. 100, A896.

30. Johanson, JF, Gargano, MA, Holland, PC, Patchen, ML, and Ueno, R (2005). Initial and sustained effects of lubiprostone, a chloride channel-2 (CIC-two) activator for the treatment of constipation: data from a iv-calendar week phase Iii study. Am J Gastroenterol. 100, A884.

31. Johanson, JF, Gargano, MA, The netherlands, PC, Patchen, ML, and Ueno, R (2003). Phase III efficacy and safety of RU-0211, a novel chloride aqueduct activator, for the treatment of constipation. Gastroenterology. 124, A48.

    

32. Johanson, JF, Gargano, MA, Holland, PC, Patchen, ML, and Ueno, R (2004). Phase Three, randomized withdrawal study of RU-0211, a novel chloride channel activator for the handling of constipation. Gastroenterology. 126, A100.

33. Higgins, JPT, and Green, South (2011). Cochrane Handbook for Systematic Reviews of Interventions version five.1.0 [updated March 2011].Available from URL: http://handbook.cochrane.org/" target="_blank">http://handbook.cochrane.org/

34. Review Manager (Rev Man) [Computer programme]. (2008). Version v.0.Available from URL: http://tech.cochrane.org/revman/download/windows64" target="_blank">http://tech.cochrane.org/revman/download/windows64

35. DerSimonian, R, and Laird, N (1986). Meta-assay in clinical trials. Control Clin Trials. 7, 177-188.

    

36. Demets, DL (1987). Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 6, 341-350.

    

37. Higgins, JP, and Thompson, SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med. 21, 1539-1558.

    

38. Egger, M, Smith, GD, and Altman, DG (2001). Systematic reviews in healthcare: meta-assay in context. London: BMJ Publication group

    

39. Egger, 1000, Smith, GD, and Altman, DG (2001). Systemic reviews in wellness care: meta-assay in context. Statistical methods for examining heterogeneity and combining results from several studies in meta-assay, Deeks, JJ, and Altman, DG, ed. London: BMJ Publication group, pp. 285-312

40. Jadad, AR, Moore, RA, and Carroll, D (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 17, one-12.

    

41. Chalmers, TC, Smith, H, and Blackburn, B (1981). A method for assessing the quality of a randomized control trial. Control Clin Trials. 2, 31-49.

    

43. Bouras, EP, Camilleri, M, Burton, DD, and McKinzie, S (1999). Selective stimulation of colonic transit by the benzofuran v-HT₄ agonist, prucalopride, in good for you humans. Gut. 44, 682-686.

    

44. Bouras, EP, Camilleri, M, Burton, DD, Thomforde, M, McKinzie, S, and Zinsmeister, AR (2001). Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 120, 354-360.

    

45. Camilleri, M, Kerstens, R, Rykx, A, and Vandeplassche, Fifty (2008). A placebo-controlled trial of prucalopride for severe chronic constipation. Due north Engl J Med. 358, 2344-2354.

    

46. Camilleri, Grand, Beyens, Chiliad, Kerstens, R, Robinson, P, and Vandeplassche, L (2009). Safety cess of prucalopride in elderly patients with constipation: a double-bullheaded, placebo-controlled study. Neurogastroenterol Motil. 21, 1256-e117.

    

47. Coremans, G, Kerstens, R, De Pauw, M, and Stevens, G (2003). Prucalopride is effective in patients with astringent chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-bullheaded, placebo-controlled clinical trial. Digestion. 67, 82-89.

    

48. Emmanuel, AV, Roy, AJ, Nicholls, TJ, and Kamm, MA (2002). Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. sixteen, 1347-1356.

    

49. Ke, M, Zou, D, and Yuan, Y (2012). Prucalopride in the handling of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 24, 999-e541.

    

50. Krogh, K, Jensen, MB, and Gandrup, P (2002). Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol. 37, 431-436.

    

51. Mugie, SM, Korczowski, B, and Bodi, P (2014). Prucalopride is no more constructive than placebo for children with functional constipation. Gastroenterology. 147, 1285-1295.

    

52. Grand?ller-Lissner, S, Rykx, A, Kerstens, R, and Vandeplassche, Fifty (2010). A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 22, 991-998.

    

53. Poen, AC, Felt-Bersma, RJ, Van Dongen, PA, and Meuwissen, SG (1999). Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal role in healthy volunteers. Aliment Pharmacol Ther. 13, 1493-1497.

    

54. Quigley, EM, Vandeplassche, Fifty, Kerstens, R, and Ausma, J (2009). Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 29, 315-328.

    

55. Sloots, CE, Poen, Ac, and Kerstens, R (2002). Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 16, 759-767.

    

56. Sloots, CE, Rykx, A, Cools, M, Kerstens, R, and De Pauw, Chiliad (2010). Efficacy and rubber of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 55, 2912-2921.

    

57. Tack, J, van Outryve, M, Beyens, G, Kerstens, R, and Vandeplassche, L (2009). Prucalopride (Resolor) in the handling of astringent chronic constipation in patients dissatisfied with laxatives. Gut. 58, 357-365.

    

58. Yiannakou, Y, Piessevaux, H, and Bouchoucha, M (2015). A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, condom, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 110, 741-718.

    

59. Emmanuel, A, Cools, K, Vandeplassche, L, and Kerstens, R (2014). Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol. 109, 887-894.

    

60. Coremans, Thou (2008). Prucalopride: the prove for its utilise in the treatment of chronic constipation. Core Evid. three, 45-54.

    

61. Pennant, One thousand, Orlando, R, Barton, P, Bayliss, S, Routh, K, and Meads, C (2011). Prucalopride for the handling of women with chronic constipation in whom standard laxative regimens accept failed to provide adequate relief. Health Technol Assess. 15, 43-50.

    

62. Shin, A, Camilleri, 1000, Kolar, G, Erwin, P, West, CP, and Murad, MH (2014). Systematic review with meta-analysis: highly selective v-HT₄ agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 39, 239-253.

    

63. Tack, J, Camilleri, Yard, and Chang, Fifty (2012). Systematic review: cardiovascular safe profile of five-HT_iv agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 35, 745-767.

    

64. Choi, SC, Zou, D, and Ke, MY (). Chronic constipation-associated symptoms in Asians and non-Asians, and furnishings of 12-week prucalopride treatment: a pooled assay of four randomized, placebo-controlled trials. J Dig Dis.

    

65. Ke, Grand, Tack, J, and Quigley, EM (2014). Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: a pooled assay of iv randomized, placebo-controlled studies. J Neurogastroenterol Motil. 20, 458-468.

    

66. Corsetti, M, and Tack, J (2014). New pharmacological treatment options for chronic constipation. Expert Opin Pharmacother. fifteen, 927-941.

    

67. Keating, GM (2013). Prucalopride: a review of its use in the management of chronic constipation. Drugs. 73, 1935-1950.

    

68. Diederen, Chiliad, Mugie, SM, and Benninga, MA (2015). Efficacy and safety of pruca-lopride in adults and children with chronic constipation. Expert Opin Pharmacother. 16, 407-416.

69. Tack, J, and Corsetti, Thou (2012). Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safe in the handling of chronic constipation. Expert Opin Drug Metab Toxicol. viii, 1327-1335.

    

klinehably1937.blogspot.com

Source: https://www.jnmjournal.org/journal/view.html?uid=1144&vmd=Full

Share this post